Referral Criteria for Hypertensive Patients to Cardiology

Resistant Hypertension

Resistant hypertension—defined as blood pressure that remains above target despite optimal doses of three antihypertensive agents (including a diuretic) or that requires four or more agents for control—warrants referral to a cardiology or hypertension specialty service for further evaluation and management. 2
Patients with resistant hypertension should undergo systematic screening for secondary causes and may benefit from specialized therapeutic options available in cardiology or dedicated hypertension centers. 2

A positive screening result (elevated plasma aldosterone‑to‑renin ratio) in any patient with resistant hypertension, unexplained hypokalemia, an incidentally discovered adrenal mass, or a family history of early‑onset hypertension or stroke (< 40 years) should trigger referral for confirmatory testing and definitive treatment planning. 2
Confirmation and management of primary aldosteronism are best coordinated by a hypertension specialist or endocrinologist in collaboration with cardiology. 2

Rare genetic forms of hypertension (e.g., Liddle’s syndrome, glucocorticoid‑remediable aldosteronism), endocrine disorders (Cushing’s syndrome, thyroid disease, hyperparathyroidism), structural vascular abnormalities (aortic coarctation), and hormonal excess states (acromegaly) should be referred to specialized centers for definitive diagnosis and therapy. 1
Suspected renovascular hypertension—particularly in older adults with a sudden rise or worsening of previously controlled blood pressure—requires specialist evaluation for possible revascularization. 2
When pheochromocytoma is suspected (e.g., abrupt severe hypertension with risk of acute organ injury), immediate referral for biochemical confirmation and surgical planning is indicated. 1

Blood pressure ≥ 180/110 mmHg accompanied by acute hypertension‑mediated organ damage (HMOD) mandates immediate cardiology consultation or emergency admission. Relevant organ injuries include:

Patients who develop hypertension secondary to anticancer therapies—especially vascular endothelial growth factor inhibitors or tyrosine‑kinase inhibitors, which cause elevated blood pressure in 80–90 % of treated individuals—should receive multidisciplinary care that includes cardiology input. 1
Coordination among oncology, hypertension specialists, cardiology, and nephrology is essential for optimal blood pressure control in this context. 1

Individuals younger than 30 years with new‑onset hypertension should be evaluated for secondary causes and considered for referral, even though primary hypertension can appear early, particularly in certain ethnic groups. 2

When the severity of target organ damage (e.g., cardiac, renal, or cerebral injury) appears out of proportion to the known duration or level of hypertension, referral is advised to investigate an underlying secondary etiology. 2

Do not postpone referral when clinical clues suggest a remediable secondary cause; approximately 10 % of hypertensive patients have a specific, treatable condition that can lead to cure or marked improvement. 2
Hypertensive urgency—markedly elevated blood pressure without acute organ damage—does not typically require cardiology referral or hospital admission; outpatient oral antihypertensive therapy is appropriate. 1
The absence of hypokalemia does not rule out primary aldosteronism, as most cases lack this laboratory finding and it has low negative predictive value. 3